Follow-Up Phone Calls May Boost Glycemic Control in T2DM

Share this content:
Follow-Up Phone Calls May Boost Glycemic Control in T2DM
Follow-Up Phone Calls May Boost Glycemic Control in T2DM

FRIDAY, Nov. 18, 2016 (HealthDay News) -- For patients with type 2 diabetes, follow-up phone calls after a monthly clinic visit could lead to clinically significant change in hemoglobin A1C (HbA1c) levels, according to a study published online Nov. 13 in the Journal of Clinical Nursing.

Cheryl Brown-Deacon, D.N.P., from the University of Michigan-Flint, and colleagues conducted a quality improvement study to examine the effectiveness of follow-up phone calls in improving frequency of glucose monitoring over a three-month period in patients with type 2 diabetes. A total of 41 patients with type 2 diabetes with HbA1c ≥7.5 percent were included in the study. Over a three-month period, patients were assigned to receive standard care (Group 1) or to receive standard care plus follow-up phone calls within two weeks after a monthly clinic visit (Group 2).

The researchers observed no statistically significant between-group differences in the baseline HbA1c or the three-month HbA1c. The mean HbA1c change did not differ significantly between Groups 1 and 2. There were no statistically significant differences between the groups in the number of patients who kept logs of their blood glucose readings.

"The intervention using telephone follow-up calls did not show a statistically significant improvement in overall HbA1c, but there was a clinically significant change in HbA1c in the group of patients that received follow-up phone calls," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »